Stone Summit Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Stone Summit Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Hold	10,335	–	–	0.09%	120
2026 Q1	$311K	Sell	10,335 -685	-6%	-$22K	0.09%	120
2025 Q4	$344K	Hold	11,020	–	–	0.09%	117
2025 Q3	$223K	Hold	11,020	–	–	0.06%	138
2025 Q2	$185K	Sell	11,020 -2,000	-15%	-$32.3K	0.06%	142
2025 Q1	$200K	Hold	13,020	–	–	0.07%	140
2024 Q4	$287K	Hold	13,020	–	–	0.1%	123
2024 Q3	$235K	Hold	13,020	–	–	0.08%	137
2024 Q2	$212K	Hold	13,020	–	–	0.08%	134
2024 Q1	$184K	Hold	13,020	–	–	0.06%	140
2023 Q4	$136K	Hold	13,020	–	–	0.05%	139
2023 Q3	$133K	Hold	13,020	–	–	0.06%	138
2023 Q2	$98K	Hold	13,020	–	–	0.04%	137
2023 Q1	$115K	Hold	13,020	–	–	0.05%	133
2022 Q4	$119K	Hold	13,020	–	–	0.06%	130
2022 Q3	$105K	Hold	13,020	–	–	0.06%	123
2022 Q2	$98K	Buy	13,020 +20	+0.2%	+$174	0.06%	129
2022 Q1	$122K	Buy	13,000 +2,000	+18%	+$16.7K	0.07%	129
2021 Q4	$88K	Buy	+11,000	New	+$99.3K	0.07%	103

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Stone Summit Wealth's TEVA Position: Q2 2026 in Review

Stone Summit Wealth held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 10,335 shares worth $350K. The position accounts for 0.09% of the portfolio, ranked #120.

Stone Summit Wealth first reported a position in TEVA in Q4 2021 and has held it in 19 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Stone Summit Wealth held 10,335 shares of Teva Pharmaceuticals worth $350K as of Q2 2026.
Stone Summit Wealth left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.09% of Stone Summit Wealth's portfolio in Q2 2026, its #120 holding.
Stone Summit Wealth first reported a position in Teva Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Stone Summit Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.